Idec Zevalin Targets Up To 40,000 Rituxan-Refractory NHL Patients
Executive Summary
Idec's Zevalin is expected to target the 30% of non-Hodgkin's lymphoma patients refractory to Idec/ Genentech's Rituxan (rituximab), Idec President Bill Rohn said
You may also be interested in...
Idec Zevalin NHL Indication Split By Accelerated/Standard Approval
Idec/Genentech will conduct a postmarketing study of Zevalin in non-Hodgkin's lymphoma patients who have not failed Rituxan therapy to fulfill accelerated approval requirements
Idec Zevalin Approval Delayed By Manufacturing Issues At Catalytica
The delay in FDA approval of Idec's non-Hodgkin's lymphoma treatment Zevalin could also cause a delay in finalizing Medicare reimbursement for the product
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011